//
Robin Kate Kelley
Lorenza Rimassa
Baek-Yeol Ryoo
Joong-Won Park
Jean-Frdric Blanc
Stephen Lam Chan
Vincenzo Dadduzio
Thomas Cheung Yau
Suvajit Sen
David W. Markby
Rajesh Kaldate
Anthony B. El-Khoueiry
Ann-Lii Cheng
Tim Meyer
Ghassan K. Abou-Alfa
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Humanitas Clinical and Research Center, Rozzano, Italy
Surgery, , Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
National Cancer Center Korea, Goyang-Si, Korea, Republic of (South)
Service dHepato-Gastroenterologie et dOncologie Digestive, Groupe Hospitalier Saint Andre, Bordeaux, France
Department of Clinical Oncology, State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Exelixis, Alameda, CA
USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan
University College London Hospitals/UCL Cancer Institute, London, United Kingdom
Memorial Sloan Kettering Cancer Center, Port Washington, NY
United States
Italy
France
Hong Kong
Taiwan
United Kingdom
Republic of South Korea
Exelixis, Inc.
Oncology (ONC)
Liver cancer
Alpha-fetoprotein
Cabozantinib
Sorafenib
N/A
Randomized
Placebo Control
Prospective
NA
NCT01908426
N/A
N/A